On Weighted Log-Rank Combination Tests and Companion Cox Model Estimators

Larry F. León (), Ray Lin and Keaven M. Anderson
Additional contact information
Larry F. León: Celgene
Ray Lin: Genentech
Keaven M. Anderson: Merck Research Laboratories

Statistics in Biosciences, 2020, vol. 12, issue 2, No 10, 225-245

Abstract: Abstract In randomized clinical trials, the log-rank test and Cox proportional hazards model are the gold standard in survival data analyses. While the log-rank test is generally valid, in the presence of non-proportional hazards, the power can be substantially decreased relative to the proportional hazards assumptions under which studies are usually designed. In contrast, weighted log-rank tests can be more powerful for specific treatment differences under non-proportional hazards scenarios. However, a poor choice of the weighting form can be detrimental. Recent work on combining various weighted log-rank tests allows for tests that are capable of detecting treatment effects across a broad range of non-proportional hazards scenarios. In this paper, we expand on these ideas with a framework based on a flexible resampling approach [5] which allows for the combination of various testing procedures in addition to weighted log-rank tests. In particular, we describe how tests based on restricted mean survival time (RMST) comparisons can be included within combinations of weighted log-rank tests as well as other test statistics such as Tarone-Ware and Renyi-type supremum families. For estimation, we propose companion weighted Cox model estimators [14, 21, 22] which utilize the weighting form that is “selected” through the combination test and provide simultaneous confidence intervals. The performance of various combinations and their companion Cox estimators as well as RMST are evaluated in simulation studies under null, proportional hazards, late-separation, and early-separation scenarios. We find the combination tests perform quite well in controlling type-1 error rates and in achieving higher power than individual tests across the scenarios considered here. We suggest the companion Cox estimators are a natural link to the testing procedures and can be a useful complementary summary of treatment effects with careful interpretation. For illustration, we apply the proposals to a randomized clinical trial study of the PD-L1-targeted therapy atezolizumab in comparison with docetaxel in previously treated non-small-cell lung cancer patients. R code can be found at https://github.com/larryleon/combination-tests-and-estimators.

Keywords: Weighted Cox model; Non-proportional hazards; Weighted log-rank test; Combination test; Restricted mean survival time (RMST) (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s12561-020-09276-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:stabio:v:12:y:2020:i:2:d:10.1007_s12561-020-09276-1

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/12561

DOI: 10.1007/s12561-020-09276-1

Access Statistics for this article

Statistics in Biosciences is currently edited by Hongyu Zhao and Xihong Lin

More articles in Statistics in Biosciences from Springer, International Chinese Statistical Association
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().